dc.contributor.author | Lou, Hao | |
dc.contributor.author | Hageman, Michael J. | |
dc.date.accessioned | 2023-06-13T15:46:49Z | |
dc.date.available | 2023-06-13T15:46:49Z | |
dc.date.issued | 2023-03-22 | |
dc.identifier.citation | Lou, H., Hageman, M.J. Development of Drug Release Model for Suspensions in ESCAR (Emulator of SubCutaneous Absorption and Release). AAPS J 25, 29 (2023). https://doi.org/10.1208/s12248-023-00799-1 | en_US |
dc.identifier.uri | https://hdl.handle.net/1808/34349 | |
dc.description.abstract | We recently developed an in vitro testing system, namely, ESCAR (Emulator of SubCutaneous Absorption and Release). The objective of this work was to investigate drug release behaviors of unmilled and milled suspensions in ESCAR. A mass transport-based model was developed to describe the multi-step drug release process, including drug dissolution, particle settling, drug distribution/partition, and drug permeation through the membrane(s). To address the particle settling effect, a correction factor was included in the model and its value was obtained by data fitting. It was found that, for both suspensions, (i) the experimental data of various dose/formulation combinations could be fit by the developed model; (ii) the dose effect on drug release was offset by the particle settling effect. This model may help to reduce experimental efforts and facilitate subcutaneous suspension formulation development using ESCAR. | en_US |
dc.publisher | Springer | en_US |
dc.rights | Copyright © 2023, The Author(s), under exclusive license to American Association of Pharmaceutical Scientists. | en_US |
dc.subject | Drug release | en_US |
dc.subject | In vitro system | en_US |
dc.subject | Mass transport | en_US |
dc.subject | Subcutaneous route of administration | en_US |
dc.subject | Suspension | en_US |
dc.title | Development of Drug Release Model for Suspensions in ESCAR (Emulator of SubCutaneous Absorption and Release) | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Lou, Hao | |
kusw.kuauthor | Hageman, Michael J. | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
kusw.kudepartment | Biopharmaceutical Innovation and Optimization Center | en_US |
dc.identifier.doi | 10.1208/s12248-023-00799-1 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC10184886 | en_US |
dc.rights.accessrights | embargoedAccess | en_US |